Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC) HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits tumor growth in preclinical squamous cell…
